News

BREO ELLIPTA is a fixed dose combination of the inhaled corticosteroid, fluticasone furoate (FF) and the long-acting beta2 agonist (LABA), vilanterol (VI), administered using the ELLIPTA inhaler. The

Lucentis is a vascular endothelial growth factor (VEGF) inhibitor, designed to bind to and inhibit VEGF-A, a protein that is believed to play a major role in the

The EMA submission includes the registration of a new 25mg Powder for Oral Suspension formulation for eltrombopag and also a new 12.5mg tablet. The drug is indicated to

As part of the deal, Adimab will use its proprietary platform to produce therapeutic antibodies and bispecifics molecules against multiple targets, which will be developed and commercialized by

Velcade was approved for use in combination with rituximab, cyclophosphamide, doxorubicin and prednisone to treat MCL patients who are unsuitable for blood stem-cell transplantation. Currently, Velcade is indicated

The facility, which is expected to come online in early 2016, will support Juno’s planned JCAR015 multicenter clinical trial, additional clinical programs in Juno’s pipeline, and the company’s

In addition, the Russian Patent Office issued a first notification to grant patent coverage of the Company’s lead therapeutic candidate, NNI-351, for pharmaceutical composition and a method of

Going forward, the "ChromaDex Quality Verified Seal" will be added to the entire line of BPI Sports’ protein powders, assuring that each product has been third-party tested and

The first patients out of a planned total of 600 patients with colorectal cancer treated with chemotherapy have been dosed in the trial. Elsiglutide is a novel GLP-2